Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sotera Health CoSHC +0.60%76 Days Sales Outstanding is 40.86 as of Jun. 2026, which is 7% below its 10-year median of 44.05. GuruFocus rates SHC with a GF Score™ of 76/100 and a GF Value™ of $16.45 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 201 Medical Diagnostics & Research companies, Sotera Health Co ranks better than 77.61% on this metric.
The historical rank and industry rank for Sotera Health Co's Days Sales Outstanding or its related term are showing as below:
SHC'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 39.17 Med: 44.05 Max: 48.92
Current: 42.38
During the past 8 years, Sotera Health Co's highest Days Sales Outstanding was 48.92. The lowest was 39.17. And the median was 44.05.
SHC's Days Sales Outstanding is ranked better than 77.61% of 201
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.59
vs SHC: 42.38
Sotera Health Co's Days Sales Outstanding
declined
from Jun. 2025 (41.02) to Jun. 2026 (40.86).
Sotera Health Co (NAS:SHC) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Sotera Health Co Days Sales Outstanding Related Terms
Sotera Health Co Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Sotera Health Co's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHC vs RDNT, BLLN, ADPT: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Sotera Health Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sotera Health Co Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Sotera Health Co's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Sotera Health Co's Days Sales Outstanding falls into.
Sotera Health Co Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sotera Health Co (SHC) has a Days Sales Outstanding of 40.86 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sotera Health Co and its competitors. This is near median its historical median of 44.05. Over the past decade, Sotera Health Co's Days Sales Outstanding has ranged from 39.17 to 48.92. According to the industry distribution chart, Sotera Health Co ranks #45 out of 201 companies in the Medical Diagnostics & Research industry, placing it in the top 22.4%.
Is Sotera Health Co's Days Sales Outstanding too high?
Sotera Health Co's current Days Sales Outstanding of 40.86 is near median its 10-year median of 44.05. Over the past 10 years, this metric has ranged from a low of 39.17 to a high of 48.92. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.59. Sotera Health Co's value of 40.86 is 39.5% below this industry median. Based on the distribution chart, Sotera Health Co ranks #45 out of 201 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Sotera Health Co has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sotera Health Co's Days Sales Outstanding compare to RDNT and BLLN?
According to the Medical Diagnostics & Research industry distribution chart, Sotera Health Co ranks #45 out of 201 companies for Days Sales Outstanding. This places Sotera Health Co in the top 22% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.59. Sotera Health Co's value of 40.86 is 39.5% below this benchmark. Historically, Sotera Health Co's own Days Sales Outstanding has ranged from 39.17 to 48.92 over the past decade. While the company's 10-year median is 44.05 vs. the industry median of 67.59, Sotera Health Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.59, based on 201 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sotera Health Co's current Days Sales Outstanding of 40.86 is 39.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Sotera Health Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sotera Health Co's current Days Sales Outstanding is 40.86, which is near median its own 10-year median of 44.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sotera Health Co stock overvalued right now?
Based on GuruFocus' analysis, Sotera Health Co (SHC) is currently considered Modestly Overvalued. The stock's GF Value™ is $16.45, compared to a current price of $18.37 — trading 11.7% above its estimated fair value. The current Days Sales Outstanding is 40.86, which is near median its 10-year median of 44.05 and 39.5% below the Medical Diagnostics & Research industry median of 67.59. Sotera Health Co's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Sotera Health Co (SHC), the current Days Sales Outstanding is 40.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sotera Health Co (SHC) Overvalued in 2026?
Based on GuruFocus' analysis, Sotera Health Co stock appears to be overvalued.
The current stock price of $18.37 is trading 11.7% above its estimated GF Value™ of $16.45.
GuruFocus considers Sotera Health Co to be Modestly Overvalued.
Key valuation signals for SHC:
Days Sales Outstanding: 40.86 (near median its 10-year median of 44.05)
GF Value™: $16.45 vs. price of $18.37 (11.7% above fair value)
Industry Position: 39.5% below the Medical Diagnostics & Research median (#45 of 201)
No single metric tells the full story. See the SHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical, and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three reportable segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment, which generates maximum revenue, provides outsourced terminal sterilization and irradiation services for medical devices, pharmaceuticals, food safety, and other application markets using three core technologies: gamma irradiation, EO processing, and E-beam irradiation. Geographically, the company generates maximum revenue from the United States, followed by Canada, Europe, and other regions.
76GF Score
Get the complete analysis for SHC
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHC has been successfully added to your 
